905811-04-3

Basic information

• Product Name: CHEMBRDG-BB 4024637
• Synonyms: CHEMBRDG-BB 4024637;N-(3-Aminophenyl)-4-chlorobenzamide;AKOS BBV-012377;UKRORGSYN-BB BBV-012377;N-(3-aminophenyl)-4-chlorobenzamide(SALTDATA: FREE)
• CAS NO: 905811-04-3
• Molecular Formula: C₁₃H₁₁ClN₂O
• Molecular Weight: 246.7
• Mol File: 905811-04-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 348.351°C at 760 mmHg
• Flash Point: 164.477°C
• Appearance: /
• Density: 1.351g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.692
• PKA: 12.85±0.70(Predicted)
• CAS DataBase Reference: CHEMBRDG-BB 4024637(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 4024637(905811-04-3)
• EPA Substance Registry System: CHEMBRDG-BB 4024637(905811-04-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 905811-04-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H11ClN2O/c14-10-6-4-9(5-7-10)13(17)16-12-3-1-2-11(15)8-12/h1-8H,15H2,(H,16,17)

Upstream product

• 6282-15-1 4-chloro-benzoic acid-(3-nitro-anilide) 
• 99-09-2 3-nitro-aniline 
• 122-01-0 4-chloro-benzoyl chloride 
• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 

Downstream Products

• 25304-24-9 4-Chloro-N-[3-(2,2-dimethyl-propionylamino)-phenyl]-benzamide 
• 25228-81-3 4-Chloro-N-(3-propionylamino-phenyl)-benzamide 
• 1192927-83-5 3,4,5-trimethoxy-N-((3-(4-chlorobenzoyl)aminophenylamino)carbonothioyl)benzamide 
• 1192928-19-0 N-(3-(4-chlorobenzoylamino-2-methylphenyl-amino)carbonyl)-3,4,5-trimethoxybenzamide 
• 330821-83-5 C₂₀H₁₅ClN₂O₂ 

Relevant articles and documents

Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking

Herein, we embarked on a structural optimization campaign aiming at the discovery of novel anticancer agents with our previously reported XL-6f as a lead compound. A library of 23 compounds has been synthesized based on the highly conserved active site of VEGFR-2. Several title compounds exhibited selective inhibitory activities against VEGFR-2, which also displayed selective anti-proliferation potency against HepG2 cell. All synthesized compounds were evaluated for anti-angiogenesis capability. Compound 7o showed the most potent anti-angiogenesis ability, the efficient cytotoxic activities (in vitro against HUVEC and HepG2 cell lines with IC50 values of 0.58 and 0.23 μM, respectively). The molecular docking analysis revealed 7o is a Type-II inhibitor of VEGFR-2 kinase. In general, these results indicated these arylamide-5-anilinoquinazoline-8-nitro derivatives are promising inhibitors of VEGFR-2 for the potential treatment of anti-angiogenesis.

Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity

The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.